Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7437.091 | 0.0091 | -1.0000 | 0.3419 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7440.091 | 0.9107 | 0.6048 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7440.091 | 0.9708 | 0.8653 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7440.091 | 0.9836 | 0.9236 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7440.091 | 0.9759 | 0.8885 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7440.091 | 0.9633 | 0.8315 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7440.091 | 0.9411 | 0.7337 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7440.091 | 0.7938 | 0.1617 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7440.091 | 0.0108 | -1.0000 | 0.4250 | |
| HCC1419 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7440.091 | 0.0077 | -1.0000 | 0.4250 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7441.09 | 1.0223 | 1.0610 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7441.09 | 1.0239 | 1.0656 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7441.09 | 0.9910 | 0.9755 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7441.09 | 0.9874 | 0.9657 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7441.09 | 1.0172 | 1.0472 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7441.09 | 0.9277 | 0.8054 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7441.09 | 0.6906 | 0.2069 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7441.09 | 0.0151 | -0.9935 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7441.09 | 0.0061 | -0.9981 | 0.7331 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7442.092 | 0.9671 | 0.9164 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7442.092 | 0.9637 | 0.9076 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7442.092 | 1.0005 | 1.0013 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7442.092 | 1.0212 | 1.0542 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7442.092 | 1.0141 | 1.0360 | 0.7831 | |
| HCC1428 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7442.092 | 0.9881 | 0.9697 | 0.7831 |